These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 30200779)
1. An evaluation of tedizolid for the treatment of MRSA infections. Hall RG; Smith WJ; Putnam WC; Pass SE Expert Opin Pharmacother; 2018 Sep; 19(13):1489-1494. PubMed ID: 30200779 [TBL] [Abstract][Full Text] [Related]
2. Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA. McCool R; Gould IM; Eales J; Barata T; Arber M; Fleetwood K; Glanville J; Kauf TL BMC Infect Dis; 2017 Jan; 17(1):39. PubMed ID: 28061827 [TBL] [Abstract][Full Text] [Related]
3. Tedizolid and Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections of the Lower Extremity versus Non-Lower-Extremity Infections Joseph WS; Culshaw D; Anuskiewicz S; De Anda C; Prokocimer P J Am Podiatr Med Assoc; 2017 Jul; 107(4):264-271. PubMed ID: 27533787 [TBL] [Abstract][Full Text] [Related]
4. Tedizolid: a new oxazolidinone antimicrobial. Kisgen JJ; Mansour H; Unger NR; Childs LM Am J Health Syst Pharm; 2014 Apr; 71(8):621-33. PubMed ID: 24688035 [TBL] [Abstract][Full Text] [Related]
8. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021 [TBL] [Abstract][Full Text] [Related]
9. The role of tedizolid in skin and soft tissue infections. Bouza E; Muñoz P; Burillo A Curr Opin Infect Dis; 2018 Apr; 31(2):131-140. PubMed ID: 29346119 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of tedizolid and other comparator drugs in methicillin-resistant Staphylococcus aureus isolates in skin and soft tissue infections in seven Colombian hospitals. Leal AL; Ovalle MV; Cortés JA; Montañes AM; De la Rosa ZR; Rodríguez JY; Gualtero S; Ariza B; Sussman O; Torres MDP Biomedica; 2018 Dec; 38(4):507-513. PubMed ID: 30653864 [TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan - Results of a randomised, multicentre phase 3 study. Mikamo H; Takesue Y; Iwamoto Y; Tanigawa T; Kato M; Tanimura Y; Kohno S J Infect Chemother; 2018 Jun; 24(6):434-442. PubMed ID: 29530544 [TBL] [Abstract][Full Text] [Related]
12. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials. Lodise TP; Fang E; Minassian SL; Prokocimer PG Antimicrob Agents Chemother; 2014 Dec; 58(12):7198-204. PubMed ID: 25246392 [TBL] [Abstract][Full Text] [Related]
13. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance. Rybak JM; Marx K; Martin CA Pharmacotherapy; 2014 Nov; 34(11):1198-208. PubMed ID: 25266820 [TBL] [Abstract][Full Text] [Related]
14. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model. Keel RA; Tessier PR; Crandon JL; Nicolau DP Antimicrob Agents Chemother; 2012 Aug; 56(8):4403-7. PubMed ID: 22687504 [TBL] [Abstract][Full Text] [Related]
15. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Stein GE; Wells EM Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750 [TBL] [Abstract][Full Text] [Related]
16. Activity of linezolid and tedizolid against clinical isolates of methicillin-resistant and methicillin and linezolid resistant Staphylococcus aureus: an in vitro comparison. Peñuelas M; Candel FJ; Lejarraga C; López-González L; Viñuela-Prieto JM; López de Mendoza D Rev Esp Quimioter; 2016 Oct; 29(5):255-8. PubMed ID: 27374726 [TBL] [Abstract][Full Text] [Related]
17. Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections. Ferrández O; Urbina O; Grau S Drug Des Devel Ther; 2017; 11():65-82. PubMed ID: 28053508 [TBL] [Abstract][Full Text] [Related]
18. Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Kanafani ZA; Corey GR Expert Opin Investig Drugs; 2012 Apr; 21(4):515-22. PubMed ID: 22324973 [TBL] [Abstract][Full Text] [Related]
19. Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections. Hall RG; Michaels HN Infect Drug Resist; 2015; 8():75-82. PubMed ID: 25960671 [TBL] [Abstract][Full Text] [Related]
20. Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic. Burdette SD; Trotman R Clin Infect Dis; 2015 Oct; 61(8):1315-21. PubMed ID: 26105167 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]